|
1.
|
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 -  10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
|
2.
|
|
12 p, 3.0 MB |
Epitope characterization of a monoclonal antibody that selectively recognizes allotypes
/
Falco, Michela (IRCCS Istituto Giannina Gaslini) ;
Meazza, Raffaella (IRCCS Ospedale Policlinico San Martino) ;
Alicata, Claudia (IRCCS Ospedale Pediatrico Bambino Gesù) ;
Canevali, Paolo (IRCCS Ospedale Policlinico San Martino) ;
Muntasell i Castellví, Aura 1972- (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bottino, Cristina (DIMES, University of Genoa) ;
Moretta, Lorenzo (IRCCS Ospedale Pediatrico Bambino Gesù) ;
Pende, Daniela (IRCCS Ospedale Policlinico San Martino) ;
Lopez-Botet, Miguel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Killer immunoglobulin-like receptor (KIR) genes code for a family of inhibitory and activating receptors, finely tuning NK cell function. Numerous studies reported the relevance of KIR allelic polymorphism on KIR expression, ligand affinity, and strength in signal transduction. [...]
2022 - 10.1111/tan.14630
Hla, Vol. 100 (june 2022) , p. 107-118
|
|
|
3.
|
|
17 p, 534.5 KB |
COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
/
Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Barlesi, Fabrice (Gustave Roussy) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Chu, Quincy (Cross Cancer Institute) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ;
Dakhil, Shaker (Cancer Center of Kansas) ;
Camidge, D (University of Colorado Anschutz Medical Campus) ;
Winzer, Leanne (AstraZeneca) ;
Soo-Hoo, Yee (AstraZeneca) ;
Cooper, Zachary A. (AstraZeneca) ;
Kumar, Rakesh (AstraZeneca) ;
Bothos, John (AstraZeneca) ;
Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227
|
|
|
4.
|
|
14 p, 2.8 MB |
Characterization of + cell subsets with a monoclonal antibody selectively recognizing and blocking the specific interaction with
/
Meazza, Raffaella (IRCCS Ospedale Policlinico San Martino) ;
Falco, Michela (IRCCS Istituto Giannina Gaslini) ;
Canevali, Paolo (IRCCS Ospedale Policlinico San Martino) ;
Loiacono, Fabrizio (IRCCS Ospedale Policlinico San Martino) ;
Colomar-Carando, Natalia (University of Genoa) ;
Muntasell i Castellví, Aura 1972- (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rea, Anna (Universitat Pompeu Fabra) ;
Mingari, Maria Cristina (University of Genoa) ;
Locatelli, Franco (Sapienza University) ;
Moretta, Lorenzo (IRCCS Ospedale Pediatrico Bambino Gesù) ;
Lopez-Botet, Miguel (Universitat Pompeu Fabra) ;
Pende, Daniela (IRCCS Ospedale Policlinico San Martino) ;
Universitat Autònoma de Barcelona
The phenotypic identification of different NK cell subsets allows more in-depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. [...]
2022 - 10.1111/tan.14640
Hla, Vol. 100 (may 2022) , p. 119-132
|
|
|
5.
|
|
9 p, 1.4 MB |
Treatment patterns of monoclonal antibodies in patients with severe uncontrolled asthma treated by pulmonologists in Spain
/
Casas-Maldonado, Francisco (Hospital Universitario San Cecilio (Granada)) ;
Álvarez Gutiérrez, Francisco Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Blanco-Aparicio, Marina (Complejo Hospitalario Universitario de A Coruña) ;
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Cisneros, Carolina (Hospital Universitario de la Princesa (Madrid)) ;
Soto-Campos, Gregorio (Hospital Universitario de Jerez (Jerez de la Frontera)) ;
Román Bernal, Berta (Hospital Dr. José Molina Orosa, Lanzarote) ;
González-Barcala, Francisco Javier (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Universitat Autònoma de Barcelona
Introduction and objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or more of these targeted treatments, based on different clinical criteria, a global vision of mAb prescription management in a large sample of hospitals is not well characterised in Spain. [...]
Introducción y objetivos: El uso de terapias basadas en anticuerpos monoclonales (mAb) se está convirtiendo en el nuevo estándar de atención para el asma grave no controlada (AGNC). A pesar de que los pacientes pueden optar a uno o varios de estos tratamientos dirigidos, con base en diferentes criterios clínicos, en España no se ha caracterizado bien una visión global de la gestión de la prescripción de mAb en una gran muestra de hospitales. [...]
Elsevier España, 2023 - 10.1016/j.opresp.2023.100252
Open Respiratory Archives, Vol. 5 Num. 3 (jul. 2023) , art. 100252
|
|
|
6.
|
|
27 p, 1.3 MB |
Documento de consenso de asma grave en adultos. Actualización 2022
/
Alvarez Gutiérrez, Francisco Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Blanco-Aparicio, Marina (Complejo Hospitalario Universitario de A Coruña) ;
Casas-Maldonado, Francisco (Hospital Universitario San Cecilio (Granada)) ;
Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ;
González-Barcala, Francisco Javier (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Carretero-García, José Ángel (Servicio de Neumología. Hospital Royo Villanova) ;
Castilla-Martínez, Manuel (Servicio de Neumología. Hospital Universitario Los Arcos del Mar Menor) ;
Cisneros, Carolina (Servicio de Neumología. Hospital Universitario La Princesa. FIB La Princesa) ;
Diaz-Pérez, David (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Martínez-Moragon, Eva (Servicio de Neumología. Hospital Universitario Dr Peset) ;
Muñoz Gall, Xavier (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Padilla, Alicia (Unidad de Asma. Hospital Costa del Sol) ;
Perpiñá-Tordera, Miguel (Hospital Universitari i Politècnic La Fe (València)) ;
Soto-Campos, Gregorio (Unidad de Gestión Clínica de Neumología y Alergia. Hospital Universitario de Jerez)
El asma grave constituye un síndrome heterogéneo con diversas variantes clínicas, y representa en muchas ocasiones una enfermedad compleja con necesidad de un abordaje especializado y multidisciplinar, así como la utilización de múltiples fármacos. [...]
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. [...]
2022 - 10.1016/j.opresp.2022.100192
Open Respiratory Archives, Vol. 4 (2022) , p. 100192
|
|
|
7.
|
|
9 p, 430.4 KB |
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
/
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Maspero, Jorge F (Fundación CIDEA) ;
Castro, Mario (University of Kansas School of Medicine) ;
Hanania, Nicola A. (Baylor College of Medicine) ;
Ford, Linda B (Asthma & Allergy Center) ;
Halpin, David M G (College of Medicine and Health) ;
Jackson, David J (King's College London) ;
Daizadeh, Nadia (Sanofi-Syntelabo) ;
Djandji, Michel (Sanofi-Syntelabo) ;
Mitchell, Colin P (Sanofi-Syntelabo) ;
Crikelair, Nora (Regeneron Pharmaceuticals. Inc) ;
Jacob-Nara, Juby A (Sanofi-Syntelabo) ;
Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ;
Rowe, Paul J (Sanofi-Syntelabo) ;
Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. [...]
2022 - 10.1016/j.jaip.2022.03.020
The Journal of allergy and clinical immunology. In practice, Vol. 10 Núm. 7 (July 2022) , p. 1835-1843
|
|
|
8.
|
|
10 p, 577.6 KB |
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
/
Mantegazza, Renato (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Wolfe, Gil I. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Muppidi, Srikanth (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Wiendl, Heinz (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Fujita, Kenji P. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
O'Brien, Fanny L. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Booth, Heather D.E. (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Howard, James F (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ;
Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Cortés-Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Rojas-Garcia, Ricard (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal-Fernández, Núria (Institut d'Investigació Biomèdica Sant Pau)
OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. [...]
2021 - 10.1212/WNL.0000000000011207
Neurology, Vol. 96 Núm. 4 (january 2021) , p. e610-e618
|
|
|
9.
|
|
|
10.
|
|
17 p, 1.5 MB |
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA) : Rationale, Design, and Baseline Data
/
Pagano, Gennaro (F Hoffmann-La Roche AG Research and Development Division) ;
Boess, Frank (Roche Pharma Research and Early Development) ;
Taylor, Kirsten I. (Faculty of Psychology. University of Basel) ;
Ricci, Benedicte (Roche Pharma Research and Early Development) ;
Mollenhauer, Brit ;
Poewe, Werner ;
Boulay, Anne ;
Anzures-Cabrera, Judith (Roche Products Ltd) ;
Vogt, Annamarie ;
Marchesi, Maddalena ;
Post, Anke ;
Nikolcheva, Tania ;
Kinney, Gene G. (Prothena Biosciences Inc. South San Francisco) ;
Zago, Wagner M. ;
Ness, Daniel K. ;
Svoboda, Hanno (F. Hoffmann-La Roche) ;
Britschgi, Markus ;
Ostrowitzki, Susanne ;
Simuni, Tanya ;
Marek, Kenneth (Institute for Neurodegenerative Disorders) ;
Koller, Martin ;
Sevigny, Jeff ;
Doody, Rachelle ;
Fontoura, Paulo ;
Umbricht, Daniel ;
Bonni, Azad ;
Altendorf, Claudia ;
Anandan, Chareyna ;
Andrews, Giulia ;
Ansquer, Solène ;
Arrouasse, Raphaele ;
Aslam, Sana ;
Azulay, Jean-Philippe ;
Baker, Jeanette ;
Balaguer Martinez, Ernest ;
Barbu, Shadi ;
Bardram, Kara ;
Bega, Danny ;
Bejr-kasem, Helena (Institut d'Investigació Biomèdica Sant Pau) ;
Benatru, Isabelle ;
Benchetrit, Eve ;
Bernhard, Felix ;
Besharat, Amir ;
Bette, Sagari ;
Bichon, Amelie ;
Billnitzer, Andrew ;
Blondeau, Sophie ;
Boraud, Thomas ;
Borngräber, Freiderike ;
Boyd, James ;
Brockmann, Kathrin ;
Brodsky, Matthew ;
Brown, Ethan ;
Bruecke, Christof ;
Calvas, Fabienne ;
Canelo, Monica ;
Carbone, Federico ;
Carroll, Claire ;
Casado Fernandez, Laura ;
Cassé-Perrot, Catherine ;
Castrioto, Anna ;
Catala, Helene ;
Chan, Justine ;
Cheriet, Samia ;
Ciabarra, Aanthony ;
Classen, Joseph ;
Coleman, Juliana ;
Coleman, Robert ;
Compta, Yaroslau ;
Corbillé, Anne-Gaëlle ;
Corvol, Jean-Christophe ;
Cosgaya, Marina ;
Dahodwala, Nabila ;
Damier, Philippe ;
David, Elodie ;
Davis, Thomas ;
Dean, Marissa ;
Debilly, Berengere ;
DeGiorgio, Janell ;
Deik, Andres ;
Delaby, Laure ;
Delfini, Marie-Helene ;
Derkinderen, Pascal ;
Derost, Philipp ;
de Toledo, María ;
Deuel, Lisa ;
Diaz-Hernandez, Ann Marie ;
Dietiker, Cameron ;
Dimenshteyn, Karina ;
Dotor, Julio ;
Durif, Franck ;
Ebentheuer, Jens ;
Eggert, Karla Maria ;
Eichau Madueño, Sara ;
Eickhoff, Claudia ;
Ellenbogen, Aaron ;
Ellmerer, Philipp ;
Esparragosa Vazquez, Inés ;
Eusebio, Alexandre ;
Ewert, Siobhan ;
Fang, John ;
Feigenbaum, Danielle ;
Fluchere, Frederique ;
Foubert-Samier, Alexandra ;
Fournier, Marie ;
Fradet, Anne ;
Fraix, Valerie ;
Frank, Samuel ;
Fries, Franca ;
Galitzky, Monique ;
Gallardo Pérez, Marisol ;
Moreno, Jose Manuel García ;
Gasca, Carmen ;
Gasser, Thomas ;
Gibbons, Joyce ;
Giordana, Caroline ;
González Martinez, Alicia ;
Goodman, Ira ;
Gorospe, Arantza ;
Goubeaud, Marie ;
Grabli, David ;
Graziella, Mangone ;
Grimaldi, Stephan ;
Gross, Jeffrey ;
Guimaraes-Costa, Raquel ;
Hartmann, Andreas ;
Hartmann, Christian ;
Hassell, Travis ;
Hauser, Robert ;
Hernandez, Antonio ;
Hernández-Vara, Jorge ;
Hoeglinger, Günter ;
Homedes, Christian ;
Horta, Andrea ;
Houeto, Jean-Luc ;
Huebl, Julius ;
Hui, Jennifer ;
Isaacson, Stuart ;
Jankovic, Joseph ;
Janzen, Annette ;
Jauregui, Junior ;
Jiao, Jocelyne ;
Martí Domenech, María José ;
Joseph, Xavier ;
Kadimi, Srinath ;
Kaminski, Pat ;
Kannenberg, Silja ;
Kassubek, Jan ;
Katz, Maya ;
Klos, Kevin ;
Klos, Shannon ;
Kobet, Christopher ;
Koebert, Jennifer ;
Krause, Patricia ;
Kuehn, Andrea ;
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Kumar, Rajeev ;
Kunz, Martin ;
Kurvits, Lille ;
Kwei, Kimberly ;
Laganiere, Simon ;
Laurens, Brice ;
Levin, Johannes ;
Levy, Oren ;
LeWitt, Peter ;
Cristóbal, Gurutz Linazasoro ;
Litvan, Irene ;
Lizarraga, Karlo ;
Longardner, Katherine ;
Lopez, Rocío ;
López Manzanares, Lydia ;
Lucas del Pozo, Sara ;
Luquín Pulido, María Rosario ;
Luthra, Nijee ;
Lyons, Kelly ;
Maass, Sylvia ;
Machetanz, Gerrit ;
Macías, Yolanda ;
Maltete, David ;
Manez Miro, Jorge Uriel ;
Mariani, Louise-Laure ;
Marin, Juan ;
Marini, Kathrin ;
Marques, Ana ;
Marti, Gloria ;
Martí Domenech, María José ;
Martinez, Saul ;
Meissner, Wassilios ;
Meoni, Sara ;
Mollenhauer, Brit ;
Martinez, Dunia Mon ;
Moon, Johnson ;
Moro, Elena ;
Morrison, Peter ;
Muehlberg, Christoph ;
Multani, Manpreet ;
Murphy, Christine ;
Nicholas, Anthony ;
Pahwa, Rajesh ;
Palasí Franco, Antoni ;
Pape, Heidi ;
Patel, Neepa ;
Patel, Prity ;
Peball, Marina ;
Peckham, Elizabeth ;
Peery, Terry ;
Perez, Rafael ;
Perez, Jesús ;
Petit, Alisa ;
Pinkhardt, Elmar ;
Poewe, Werner ;
Pomies, Elsa ;
Preterre, Cecile ;
Quinn, Joseph ;
Rascol, Olivier ;
Remy, Philippe ;
Richard, Irene ;
Roeben, Benjamin ;
Ruether, Emily ;
Rumpf, Jost-Julian ;
Russell, David ;
Salhi, Hayet ;
Samaniego-Toro, Daniela ;
Samier-Foubert, Alexandra ;
Sánchez, Antonio ;
Schmitt, Emmanuelle ;
Schnitzler, Alfons ;
Schorr, Oliver ;
Schwartzbard, Julie ;
Schweyer, Kerstin ;
Seppi, Klaus ;
Sergo, Victoria ;
Shill, Holly ;
Siderowf, Andrew ;
Simuni, Tanya ;
Spampinato, Umberto ;
Sriram, Ashok ;
Stover, Natividad ;
Tanner, Caroline ;
Tarakad, Arjun ;
Taylor, Carolyn ;
Thalamus, Claire ;
Toothaker, Thomas ;
Van Blercom, Nadege ;
Vanegas-Arrogave, Nora ;
Vela, Lydia ;
Vergnet, Sylvian ;
Vidal, Tiphaine ;
Vöglein, Jonathan ;
Walsh, Ryan ;
Waters, Cheryl ;
Wegscheider, Mirko ;
Weidinger, Endy ;
Weill, Caroline ;
Wenzel, Gregor ;
Witjas, Tatiana ;
Wurster, Isabel ;
Wright, Brenton ;
Zimmermann, Milan ;
Zuzuarregui, Rafael ;
Abt, Markus ;
Bamdadian, Atieh ;
Barata, Teresa ;
Barbet, Nicholas ;
Belli, Sara ;
Boess, Frank ;
Bonni, Azad ;
Borroni, Edilio ;
Boulay, Anne ;
Britschgi, Markus ;
Chague, Jerome ;
Cosson, Valerie ;
Czech, Christian ;
Deptula, Dennis ;
Diack, Cheikh ;
Doody, Rachelle ;
Dukart, Juergen ;
D'Urso, Giulia ;
Dziadek, Sebastian (F. Hoffmann-La Roche) ;
Eddleston, Hannah ;
Edgar, Chris ;
Essioux, Laurent ;
Farell, Morgan ;
Finch, Rebecca (Roche Products Ltd) ;
Fontoura, Paulo ;
Gruenbauer, Waltraud ;
Hahn, Andreas ;
Holiga, Stefan (F. Hoffmann-La Roche) ;
Honer, Michael ;
Jadidi, Shirin ;
Johnson-Wood, Kelly ;
Keller, Markus ;
Kilchenmann, Timothy ;
Koller, Martin ;
Kremer, Thomas ;
Kustermann, Thomas (F. Hoffmann-La Roche) ;
Landsdall, Claire ;
Lindemann, Michael (F. Hoffmann-La Roche) ;
Lipsmeier, Florian ;
Luzy, Cecile ;
Manchester, Marianne ;
Marchesi, Maddalena ;
Martenyi, Ferenc ;
Martin-Facklam, Meret ;
Mironova, Katerina ;
Monnet, Annabelle (F. Hoffmann-La Roche) ;
Moore, Emma ;
Ness, Daniel K. ;
Niggli, Markus ;
Nikolcheva, Tania (F. Hoffmann-La Roche) ;
Ostrowitzki, Susanne ;
Passmard, Benedicte ;
Poirier, Agnes ;
Post, Anke ;
Prasad, Megana ;
Pross, Nathalie (F. Hoffmann-La Roche) ;
Quock, Tiffany ;
Rose, Ellen ;
Sarry, Christoph ;
Schubert, Christine ;
Selkoe, Dennis ;
Sevigny, Jeff ;
Sink, Kaycee ;
Staunton, Hannah ;
Steven, Tim ;
Strasak, Alexander ;
Svoboda, Hanno ;
Tripuraneni, Radhika ;
Trundell, Dylan ;
Umbricht, Daniel ;
Verselis, Lynne ;
Vogt, Annamarie ;
Volkova-Volkmar, Ekaterina ;
Weber, Cornelia ;
Weber, Silke ;
Zago, Wagner (Prothena Biosciences Inc. (San Francisco))
Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. [...]
2021 - 10.3389/fneur.2021.705407
Frontiers in neurology, Vol. 12 (january 2021) , p. 705407
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
